Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:BKDOTCMKTS:INVVYNASDAQ:PRVBNASDAQ:REPL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBKDBrookdale Senior Living$6.75-2.6%$6.23$3.33▼$7.05$1.28B1.321.83 million shs1.38 million shsINVVYIndivior$21.85-1.8%$21.85$14.76▼$35.50$3.01B0.353,825 shs8,100 shsPRVBProvention Bio$24.98+3.1%$24.58$3.18▼$25.00$2.37B2.472.28 million shs9.12 million shsREPLReplimune Group$6.33-1.4%$7.90$5.89▼$24.81$388.60M1.211.33 million shs631,809 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBKDBrookdale Senior Living+5.17%+9.84%+7.45%+20.03%+59.45%INVVYIndivior0.00%0.00%0.00%0.00%-5.02%PRVBProvention Bio0.00%0.00%0.00%0.00%+2.38%REPLReplimune Group0.00%-10.21%-21.71%-17.27%-64.23%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBKDBrookdale Senior Living2.4083 of 5 stars1.32.00.04.92.31.70.6INVVYIndiviorN/AN/AN/AN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/AN/AN/AN/AREPLReplimune Group4.4795 of 5 stars3.51.00.04.53.73.31.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBKDBrookdale Senior Living2.50Moderate Buy$7.5011.11% UpsideINVVYIndiviorN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AREPLReplimune Group3.00Buy$37.67495.05% UpsideCurrent Analyst RatingsLatest BKD, REPL, INVVY, and PRVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2024BKDBrookdale Senior LivingRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBKDBrookdale Senior Living$3.02B0.42$0.87 per share7.73$2.15 per share3.14INVVYIndivior$791M3.81$1.15 per share18.94$1.45 per share15.07PRVBProvention Bio$12.90M183.54N/AN/A$1.40 per share17.84REPLReplimune GroupN/AN/AN/AN/A$9.80 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBKDBrookdale Senior Living-$189.01M-$0.84N/AN/AN/A-6.27%-44.01%-3.75%5/7/2024 (Confirmed)INVVYIndivior$205M$1.0520.8112.00N/AN/AN/AN/AN/APRVBProvention Bio-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/AREPLReplimune Group-$174.28M-$3.16N/AN/AN/AN/A-42.94%-35.80%5/16/2024 (Estimated)Latest BKD, REPL, INVVY, and PRVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024N/ABKDBrookdale Senior Living-$0.17N/A+$0.17N/AN/AN/A2/20/2024Q4 2023BKDBrookdale Senior Living-$0.19-$0.40-$0.21-$0.40N/A$754.48 million2/8/2024Q3 2024REPLReplimune Group-$0.89-$0.77+$0.12-$0.77N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBKDBrookdale Senior LivingN/AN/AN/AN/AN/AINVVYIndiviorN/AN/AN/AN/AN/APRVBProvention BioN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBKDBrookdale Senior Living9.400.800.80INVVYIndiviorN/AN/AN/APRVBProvention Bio0.191.931.92REPLReplimune Group0.1612.4012.40OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBKDBrookdale Senior LivingN/AINVVYIndivior0.05%PRVBProvention Bio37.39%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipBKDBrookdale Senior Living1.50%INVVYIndiviorN/APRVBProvention Bio13.10%REPLReplimune Group20.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBKDBrookdale Senior Living25,200189.34 million186.50 millionOptionableINVVYIndivior800137.88 millionN/ANot OptionablePRVBProvention Bio8294.78 million82.37 millionNot OptionableREPLReplimune Group28461.39 million48.74 millionOptionableBKD, REPL, INVVY, and PRVB HeadlinesSourceHeadlineVontobel Holding Ltd. Takes $2.58 Million Position in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - April 19 at 5:37 AMVanguard Group Inc. Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)marketbeat.com - April 10 at 4:00 AMInterim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meetingglobenewswire.com - April 7 at 5:00 PMReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 4 at 8:00 AMFive things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is tickingbizjournals.com - March 30 at 9:59 AMReplimune appoints new CEO ahead of drug applicationuk.investing.com - March 29 at 12:50 AMPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron dealbizjournals.com - March 28 at 9:48 AMReplimune Names Sushil Patel as CEO in Broader Shakeupmarketwatch.com - March 26 at 12:12 PMReplimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEOmarkets.businessinsider.com - March 26 at 12:12 PMReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitionsglobenewswire.com - March 26 at 7:30 AMREPL Apr 2024 10.000 callfinance.yahoo.com - March 16 at 12:31 PMREPL Mar 2024 10.000 putfinance.yahoo.com - March 15 at 4:28 PMHow Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%zacks.com - March 11 at 10:56 AMWhat Makes Replimune Group, Inc. (REPL) a New Buy Stockzacks.com - March 8 at 1:01 PMReplimune to Present at the American Association for Cancer Research Annual Meeting 2024finance.yahoo.com - March 6 at 7:31 PMReplimune to Present at Three Upcoming Investor Conferencesfinance.yahoo.com - March 5 at 10:04 AMWall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?zacks.com - February 23 at 10:56 AMPositive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trialsmarkets.businessinsider.com - February 15 at 6:48 PMAnalysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)markets.businessinsider.com - February 9 at 7:41 AMReplimune Group Is Worried About This – Should You Be Worried Too?msn.com - February 9 at 7:41 AMReplimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 8 at 11:10 AMReplimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runwayfinance.yahoo.com - February 8 at 11:10 AMReplimune Group Inc (REPL)investing.com - February 8 at 12:00 AMDisc Medicine Taps Ex-Replimune Exec for CFO, Promotes New Operations Chiefmarketwatch.com - February 7 at 8:58 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to ComeCharles Schwab Fortifies its Uptrend on EPS Beat April 23, 2024 10:15 AMView Charles Schwab Fortifies its Uptrend on EPS Beat 3 High Dividend Stocks to Replace Lower Savings Yields AheadApril 9, 2024 9:15 AMView 3 High Dividend Stocks to Replace Lower Savings Yields AheadAll Headlines Company DescriptionsBrookdale Senior LivingNYSE:BKDBrookdale Senior Living Inc. owns, manages, and operates senior living communities in the United States. It operates in three segments: Independent Living, Assisted Living and Memory Care, and Continuing Care Retirement Communities (CCRCs). The Independent Living segment owns or leases communities comprising independent and assisted living units in a single community that are primarily designed for middle to upper income seniors. The Assisted Living and Memory Care segment owns or leases communities consisting of freestanding, multi-story communities and freestanding, single-story communities, which offer housing and 24-hour assistance with activities of daily living for the Company's residents. This segment also operates memory care communities for residents with Alzheimer's and other dementias. The CCRCs segment owns or leases communities that provides various living arrangements, such as independent and assisted living, memory care, and skilled nursing; and services to accommodate various levels of physical ability and healthcare needs. It also manages communities on behalf of others. Brookdale Senior Living Inc. was incorporated in 2005 and is headquartered in Brentwood, Tennessee.IndiviorOTCMKTS:INVVYIndivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.Provention BioNASDAQ:PRVBProvention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.Replimune GroupNASDAQ:REPLReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.